Cirrhosis of the liver
302 results
101 - 200
Branched‐chain amino acids for people with hepatic encephalopathy
Haematemesis and melaena - Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- Expanded polytetrafluoroethylene (ePTFE)‐covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
Rifaximin effective in decreasing post-TIPS hepatic encephalopathy in patients with cirrhosis- Bisphosphonates for osteoporosis in primary biliary cirrhosis: Cochrane systematic review
- Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta‐analysis
- Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta‐analysis
- Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta‐analysis
- Primary biliary cholangitis
- Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: Cochrane systematic review
- Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices
- Platelet count/spleen diameter ratio in predicting the presence of oesophageal varices in patients with cirrhosis
- Haemochromatosis
- Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis
- Cancer of the liver and the biliary tract
- Azathioprine for primary biliary cirrhosis
- Assessing a patient with an abnormal liver function test result
- Skin colour changes and pigmentary disorders
- Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases
- Medicinal herbs for hepatitis C virus infection
- Unintentional weight loss in adults
- Physical exercise for people with cirrhosis
- Clinical factors predict death in patients with cirrhosis + UGI bleeding
- Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis
- Metabolic syndrome
- Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease)
- Liver fibrosis stage based on the four factors (FIB‐4) score or Forns index in adults with chronic hepatitis C
- Bezafibrate for primary biliary cirrhosis: Cochrane systematic review
- Pharmacological interventions for primary biliary cholangitis
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Ribavirin plus interferon versus interferon for chronic hepatitis C
- Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices
- Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta‐analysis
- Ribavirin monotherapy for chronic hepatitis C: Cochrane systematic review
- Surgical resection versus liver transplant for patients with hepatocellular carcinoma: Cochrane systematic review
- Autoimmune hepatitis
- Probiotics for non‐alcoholic fatty liver disease and/or steatohepatitis
- Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta‐analysis
- Methods of vascular occlusion for elective liver resections: Cochrane systematic review
- Prolonged fever in the adult
- Elevated ESR (hypersedimentation)
- Platelet count, spleen length, and platelet count‐to‐spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis
- Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease
- Hyponatraemia
- Bariatric surgery (obesity surgery)
- Antioxidant supplements for liver diseases: Cochrane systematic review
- Interventions for preventing and managing advanced liver disease in cystic fibrosis
- Propylthiouracil for alcoholic liver disease: Cochrane systematic review
- Bile acids for viral hepatitis
- Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients
- Glucocorticosteroids for primary sclerosing cholangitis: Cochrane systematic review
- Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
- Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases
- Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease
- S-adenosyl-L-methionine for alcoholic liver diseases: Cochrane systematic review
- Vitamin D supplementation for chronic liver diseases in adults
- Leg cramps
- Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
- USPSTF recommendations for hepatitis B screening
- Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
- Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
- Chinese medicinal herbs for chronic hepatitis B
- Interferon for interferon naive patients with chronic hepatitis C: Cochrane systematic review
- Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis
- Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis: Cochrane systematic review
- Gynaecomastia
- Rifaximin prevents recurrent hepatic encephalopathy